Systems Medicine Combination Therapy Found Effective in Regulating Tumors
Posted on: Wednesday, 21 November 2007, 12:00 CST
Systems Medicine has reported that cumulative preliminary results of a Phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment demonstrated anti-tumor activity.
The preliminary results from the first 21 patients treated in the Phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease and half of those 14 patients having durable stable disease for more than six cycles of therapy. Toxicities were mainly hematological and were manageable and reversible in this heavily pretreated patient population. Phase II studies using this combination in patients resistant to standard therapy are planned.
The Phase I, multicenter, dose-escalation study of brostallicin in combination with cisplatin (cDDP) was conducted in patients with recurrent or metastatic solid tumors. Treatment cycles were three weeks. Brostallicin was escalated from 5 to 7 to 9mg/m2 with a fixed dose of cDDP of 75mg/m2.
The trial is based on data demonstrating tumors with high levels of GSH/GST, common in platinum-resistant disease, are more susceptible to the killing effects of brostallicin. Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models.
Source: Datamonitor
Related Articles
- BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
- Boehringer Ingelheim Presents Positive Results From Phase I Tumor Study
- Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
- Activx Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes
- Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
- Advaxis Completes Dosing and Enrollment of Third Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial
- Peregrine Initiates Patient Treatment in Bavituximab Combination Therapy Cancer Trial
- Advaxis Completes Dosing and Enrollment of First Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial
- AVANIR Announces Publication of Phase II Diabetic Neuropathic Pain Trial Results
 |
 |
User Comments (0)
RSS Feeds